GABRG1 encodes the gamma-1 subunit of GABA-A receptors, heteropentameric ligand-gated chloride channels central to inhibitory neurotransmission in the brain. The gamma-1 subunit is one of five subunits that assemble around a central pore; when GABA binds at interfaces between alpha and beta subunits, the channel opens to allow chloride influx, hyperpolarizing postsynaptic neurons and suppressing action potential generation. This inhibitory function is fundamental to neuronal signaling and synaptic plasticity. GABRG1 variants contribute to multiple neurological and psychiatric conditions. A de novo GABRG1 variant was recently identified in a child with epileptic encephalopathy, hypotonia, and global developmental delay 1, representing the first association of pathogenic GABRG1 variants with this severe phenotype. Genetic variants in GABRG1 are also implicated in alcohol dependence across multiple populations, with independent contributions to alcoholism vulnerability distinct from the nearby GABRA2 locus 23. In individuals carrying the GG genotype at rs7683876, maladaptive peer behavior shows heightened influence on externalizing behavior from late childhood through early adulthood 4. Emerging evidence suggests GABRG1 may contribute to trigeminal neuralgia susceptibility 5. Clinically, GABRG1-directed pharmacotherapy aligns with the broad GABA-A receptor drug class, including benzodiazepines (alprazolam, chlordiazepoxide), barbiturates (butalbital), and newer agents such as brexanolone and cenobamate, which modulate inhibitory signaling to treat seizures, anxiety, and related disorders.